Drug-eluting devices improved outcomes of endovascular therapy (EVT) for femoropopliteal lesions, but mainly for de novo lesions. Endovascular therapy for in-stent restenosis/occlusion (ISR/O) is challenging, and large trials and long-term data are not well reported.
Materials and Methods
This study is a physician initiated, multicenter, and retrospective design. From 7 Japanese institutes, 3635 femoropopliteal cases were enrolled in the study. Among these, 346 cases of first ISR/O were studied. We defined drug-coated-balloon, drug-eluting stent, and covered stent as New devices. Balloon angioplasty and bare nitinol stent were included in the control group.
Results
The propensity score matching extracted 112 pairs. At 12 months, the primary patency rate was 80.3% in the new device group and 52.7% in the control group, and there was a significant intergroup difference (P = .004). However, at 36 months, the rate was 43.3% vs 39.2%, with no significant difference (P = .090). No baseline characteristics had any significant interaction effect (all P > .05).
Conclusions
The New devices were more effective than the control group for ISR/O at 1 year, but caught up at 3 years.
AboyansVRiccoJBBartelinkML, et al.2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J2018;39:763-816.
2.
RosenfieldKJaffMRWhiteCJ, et al.Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153.
3.
LairdJRKatzenBTScheinertDRESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1-9.
4.
KarashimaETakaharaMHozawaK, et al.Three-year clinical outcomes of the Innova™ self-expanding nitinol stent for the treatment of femoropopliteal lesions. Cardiovasc Intervent Radiol. 2021;44:1722-1727. doi:10.1007/s00270-021-02960-9
5.
TepeGLairdJSchneiderP, et al.Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. PACT SFA randomized trial Circulation. 2015;131:495-502.
6.
GiannopoulosSStrobelARudofkerEKovachCSchneiderPAArmstrongEJ. Association of postangioplasty femoropopliteal dissections with outcomes after drug-coated balloon angioplasty in the femoropopliteal arteries. J Endovasc Ther. 2021;28:593-603.
7.
SchmidtAPiorkowskiMGornerH, et al.Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715-724.
8.
StavroulakisKTorselloGArgyriouATsilimparisNBisdasTBosiersM. 2-Year outcomes of the eluvia drug-eluting stent for the treatment of complex femoropopliteal lesionsJACC Cardiovasc Interv2021;14:692-701.
9.
LammerJZellerTHauseggerKA, et al.Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol. 2013;62:1320-1327.
10.
IchihashiSTakaharaMIidaO, et al.Clinical impact of stent graft thrombosis in femoropopliteal arterial lesions. JACC Cardiovasc Interv. 2021;14:1137-1147.
11.
VirgaVStabileEBiaminoG, et al.Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7:411-415.
12.
ZellerTDakeMDTepeG, et al.Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274-281.
13.
BosiersMDelooseKCallaertJ, et al.Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial. J Endovasc Ther. 2015;22:1-10.
14.
HorieKTanakaASuzukiKTaguriMInoueN. Long-term clinical effectiveness of a drug-coated balloon for in-stent restenosis in Femoropopliteal lesions. CVIR Endovasc. 2021;4:13.
15.
GrottiSLiistroFAngioliP, et al.Paclitaxel-eluting balloon vs standard angioplasty to reduce restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: three-year results of the DEBATE-ISR study. J Endovasc Ther. 2016;23:52-57.
16.
SteinerSSchmidtABausbackY, et al.Midterm patency after femoropopliteal interventions: a comparison of standard and interwoven nitinol stents and drug-coated balloons in a single-center, propensity score-matched analysis. Therapy. 2016;23:347-355.
17.
DakeMDAnselGMJaffMR, et al.Durable clinical effectiveness with paclitaxel- eluting stents in the femoropopliteal artery 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472-11438.
18.
TosakaAsogaYIidaO, et al.Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23.
19.
ChaJJLeeJHKoYG, et al.Clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease. Korean Circ J. 2022;52:123-133.
20.
LiXNhouMDingY, et al.A systematic review and meta-analysis of the efficacy of debulking devices for in-stent restenosis of the femoropopliteal artery. J Vasc Surg. 2020;72:356-366.
21.
BonacaMPBauersachsRMAnandSS, et al.Rivaroxaban in peripheral arteryu disease after revascularization. N Engl J Med. 2020;382:1994-11200.
22.
HessCNDebusESNehlerMR, et al.Reduction in acute limb ischemia with rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: insights from VOYAGER PAD. Circulation. 2021;144:1831-1841.
